Dutasteride are strong in the domestic hair loss treatment market. Both original and generic recorded higher sales growth than competitive drug Finasteride.

According to IQVIA, a pharmaceutical market research firm, on the 2nd, GSK Avodart's sales in the first quarter were 10.7 billion won, up 9% from 9.9 billion won in the first quarter of last year.

During the same period, Sales of Propecia fell 2% from 9.8 billion won to 9.7 billion won. The gap between Avodart and Propecia is 1.05 billion won, the largest since the second quarter of last year.

Avodart, which was used as a treatment for prostate hypertrophy, has been in the shadow of Propecia for more than a decade since i